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Summary
Macrophage migration inhibitory factor (MIF)
was the original cytokine, described almost
50 years ago and has since been revealed to
be an important player in pro-inflammatory
diseases. Recent work using MIF mouse
models has revealed new roles for MIF. In this
review, we present an increasing body of evi-
dence implicating the key pro-inflammatory
cytokine MIF in specific biological activities
related directly to cancer growth or contributing
towards a microenvironment favouring cancer
progression.
Introduction
Historically, the association between inflammation
and cancer has been well recognized. In the 1970s,
serum derived from BCG-infected endotoxin-treated
mice was shown to induce significant necrosis in
sarcoma tumour.
1 This active circulating cytokine
was identified and consequently called tumour
necrosis factor (TNF). More recently, a number of
chronic inflammatory diseases have been shown to
be associated with a variety of cancers (Table 1).
With inflammation known to contribute to cancer
development and progression, investigating the
association between these two processes has never
been more important. Macrophage migration inhibi-
tory factor (MIF) displays a number of functions
which provide a direct link between the processes
of inflammation and tumour growth.
MIF was one of the first cytokines to be described
almost 50 years ago and extensive studies since
have revealed its central role in innate and adaptive
immunity. More recently, the ability of this cytokine
to support tumour progression has become clear and
has revealed MIF as a potential target for anti-cancer
therapies.
MIF was originally identified as a T-cell-derived
factor responsible for the inhibition of macrophage
migration in experiments designed to charac-
terize delayed-type hypersensitivity.
2,3 The mol-
ecule is expressed by a variety of cells including
eosinophils,
4 epithelial cells,
5 endothelial cells,
6
lymphocytes
7 and macrophage
8 and so, predictably,
displays a wide range of activities. In vivo stimula-
tion with endotoxin promotes secretion of MIF from
pools of stored protein within the cell allowing im-
mediate amplification of the inflammatory response.
Studies showing that MIF-specific blocking antibo-
dies could attenuate endotoxic shock confirmed the
critical role that MIF plays in innate immunity.
9
The crystal structure of MIF revealed the ac-
tive form to be a 37.5kDa homotrimer with novel
protein folds that defined a new structural
! The Author(s) 2010. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial
License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Q J Med 2010; 103:831–836
doi:10.1093/qjmed/hcq148 Advance Access Publication 30 August 2010superfamily.
10,11 In addition to its distinctive struc-
ture, MIF possesses a unique enzymatic activity re-
vealed through its structural homology to several
bacterial enzymes. This tautomerase activity
mediated by an N-terminal proline residue, allows
MIF to catalyse the conversion of non-physiological
substrates D-dopachrome or L-dopachrome methyl
esters to their indole derivatives. As yet, no human
physiological substrates for MIF tautomerase have
been identified.
The discovery that MIF was secreted from cortico-
trophic pituitary cells led to its classification as a hor-
mone as well as a cytokine. Its release coincides
with, and is induced by adrenocorticotrophic hor-
mone and its ability to override the anti-
inflammatory effects of this hormone suggested an
inbuilt regulatory mechanism.
9 This ability to
promote inflammation while hindering the anti-
inflammatory effects of glucocorticoids was
implicated in the pathogenesis of acute respiratory
distress syndrome (ARDS).
12 Direct association be-
tween MIF expression levels and degrees of disease
pathogenesis in a number of inflammatory diseases
was revealed through analysis of genetic variation
within the MIF gene.
13–15 Allelic variation within a
repeat region found upstream of the MIF promoter,
determines efficiency of expression of the protein.
Individuals carrying five copies of the CATT repeat
element were found to display lower MIF levels, with
those possessing increasing numbers of repeats (6, 7
or 8) having a corresponding increase in expression.
In cystic fibrosis patients, this increase in MIF pro-
duction associated with carrying the 6 and 7 repeat
variants was associated with enhanced end-organ
injury. Rheumatoid arthritis patients carrying the 6
and 7 repeat variants had both higher basal levels
of MIF and higher levels following stimulation with
forskolin or serum. The higher levels of MIF asso-
ciated with this particular variant also correlated
with progressive disease.
16 In relation to malignant
diseases, individuals carrying the seven-repeat allele
were also found to have an increased incidence of
prostate cancer.
17 MIF biological activity has also
been implicated in the pathogenesis of atheroscler-
osis and abdominal aortic aneurysm.
18 In the context
of atherosclerosis, MIF has also been identified as a
non-cognate receptor of CXCR2 and CXCR4 and has
functional chemokine activity in evolving athero-
sclerosis mediating monocyte arrest and the forma-
tion of plaques.
19 Additionally, as part of this disease
process MIF can induce the CXCR ligand, Interleukin
(IL)-8 and regulators of macrophage infiltration
ICAM-1 and CD44, confirming its relevance in this
disease.
20
Mounting evidence suggests that inflammation is
closely associated with many types of cancer.
21
Inflammatory pathways designed to defend against
infection and injury can promote an environment
which favours tumour growth and metastasis.
Chronic inflammatory conditions and infections
have been directly linked to specific cancers, see
Table 1. Supporting this observation, treatment
with non-steroidal anti-inflammatory drugs has
been shown to reduce the risk of developing colon
cancer.
22 Consequently, there is heightened interest
both within academia and industry, to define key
regulatory events within the inflammatory process
which predispose individuals to enhanced cancer
risk. This would provide the rational for significant
investment in these high-value therapeutic targets
for drug development.
MIF and cancer
MIF’s unique biological activities have the potential
to contribute to an in vivo microenvironment fa-
vouring tumour growth and invasiveness. These
functional activities include: tumour suppressor
downregulation, COX-2 and PGE2 upregulation,
potent induction of angiogenesis and enhanced
tumour growth, proliferation and invasiveness (sum-
marized in Table 2).
MIF and the tumour suppressor p53
MIF demonstrates a direct link between inflam-
mation and tumourigenesis. As well as its estab-
lished role in inflammation, MIF directly promotes
tumourigenesis by inhibiting p53 accumulation. P53
is a classic tumour suppressor gene that can promote
cell cycle arrest and apoptosis in response to DNA
damage. Absence or downregulation of p53
Table 1 Chronic inflammatory conditions associated
with enhanced risk for specific cancers
Inflammatory
condition
Corresponding
cancer
Barrett’s oesophagus Eosophageal cancer
48
Helicobacter pylori infection Gastric cancer
49
Inflammatory bowel disease Bowel cancer
50
Hepatitis B or C Hepatocellular
carcinoma
51
Obesity-related inflammation Liver cancer
52
Tobacco-particulate induced
inflammation
Lung cancer
53
Coeliac disease Lymphoma
54
Rheumatoid arthritis Lymphoma
55
Schistosomiasis Bladder cancer
56
Osteomyelitis Sarcoma
57
832 H. Conroy et al.interferes with this important checkpoint for main-
taining genetic stability and allows cell survival and
proliferation despite the potential accumulation of
mutations. Functional screens carried out by
Hudson et al.
23 to identify cDNAs capable of nega-
tively regulating p53 identified MIF.
Over-expression of MIF down regulated p53
levels and suppressed nuclear localization, thereby
prohibiting its transcriptional activity. Most import-
antly, MIF-suppressed p53-dependent senescence
in primary mouse embryonic fibroblasts (MEFs)
and inhibited apoptosis induced by serum starva-
tion. Furthermore, in a separate study, a role for
MIF in suppression of activation-induced cell
death (AICD) was identified using MIF null
mice.
24 Lipopolysaccharide administration pro-
duced increased macrophage AICD and an asso-
ciated decrease in inflammatory cytokines in MIF
null mice compared to wild-type mice. This again
points to the key role MIF plays in amplifying in-
flammation, as well as promoting cell survival.
An important event in many cancer cells is the
activation of endogenous oncogenes such as the
prototypic oncogene Ras. Ras is a GTP-ase signal-
ling molecule capable of promoting cell prolifer-
ation and malignancy. MIF-deficient cells were
found to be resistant to p53-associated Ras oncogen-
ic transformation which is mediated downstream
through Rb and E2F. Transformation induced by
Ras was restored upon deletion of p53.
25,26
MIF receptor signalling and
tumour pathogenesis
MIF protein is found to be over-expressed in a
number of cancers and expression levels have
been found to correlate with disease severity and
invasiveness. For example, in a mouse model of
intestinal cancer, MIF expression was found to be
increased in tumour tissue relative to normal intes-
tine. In addition, MIF added exogenously to a
human colon adenocarcinoma cell line promoted
anchorage-independent growth of the cells and in-
hibited cell death.
27As well as its interactions with
tumour suppressors, MIF promotes cellular prolifer-
ation through activation of members of the MAPK
family. MIF signalling through CD74 promotes sus-
tained ERK activation. The importance of this activ-
ity is clear when you consider that this is the main
outcome of mutations in Ras which occur in a third
of human tumours.
28 MIF stimulates phosphoryl-
ation of p42/p44 MAPK through PKA. This results
in downstream activation of cPLA2 and release of
the prostaglandin precursor arachadonic acid, a po-
tential substrate for COX-2 now known to be
induced as an important element of p53 inhibition
by MIF. Sustained ERK activation is also observed in
the PC12 model of neuronal differentiation, again
suggesting a role for MIF in cell cycle progression.
29
While CD74 mediates MIF binding, a co-receptor,
CD44, is required for ERK 1 and 2 phosphoryl-
ation.
30,31 Blocking of MIF or MIF signalling, by
blocking CD74 attenutates prostate cancer invasive-
ness.
32 Conversely, activation of CD44 promotes
breast cancer cell invasion.
33 CD44+ breast cancer
cells with low or undetectable CD24 have been
found to be more tumourigenic and have a charac-
teristic ‘invasiveness gene signature’.
34 Studies have
also shown that CD44-positive prostate cancer and
breast cancer cell lines demonstrate rapid adhesion
to bone marrow endothelial cells which can be
blocked by neutralizing CD44 antibody.
35
B lymphocytes that accumulate in chronic lympho-
cytic leukaemia have been found to have high ex-
pression of CD74 and stimulation of these cells with
MIF induces anti-apoptotic Bcl-2 and promotes sur-
vival through an IL-8-dependent mechanism.
36
Blocking MIF signalling in this context decreases
using anti-CD74 antibodies decreases cell survival.
MIF, hypoxia and angiogenesis
Hypoxia is very often associated with the tumour
micro-environment. These hypoxic conditions in
turn have been found to induce in tumours expres-
sion of specific patterns of genes which confer a
survival advantage on cancer cells allowing
tumour growth and spread in this environment.
The master transcription factor HIF1a (hypoxia in-
ducible factor) binds to HREs (hypoxia response
elements) in the promoter of its target genes to acti-
vate their expression.
37 These targets include
pro-invasive and pro-angiogenic genes such as
Table 2 MIF biological activities which favour tumour
pathogenesis
MIF functional
activities
Role in tumourigenesis
P53 inhibition Accumulation of mutation
Inhibition of apoptosis
Proliferation of cells
Sustained ERK activation Promotes invasion
Inhibits cell death
COX-2/PGE-2 induction Tumour Growth
Viability
Metastasis
Endothelial cell proliferation
and differentiation
Promotes angiogenesis
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38 and Vascular endothelial growth factor
(VEGF).
39,40 Simultaneously, HIF1a negatively regu-
lates anti-angiogenic targets such as thrombospon-
din.
41 MIF is a direct transcriptional target of HIF-1a
and, more importantly, loss of MIF results in ineffi-
cient HIF-1a stabilization induced by hypoxia.
42
MIF expression has been found to be up-regulated
during hypoxia, with a HRE found in the
50Untranslated Region of the gene.
43,44 MIF also
supports tumour growth in a hypoxic environment
through significantly enhancing angiogenesis.
Through the activation of MAP kinases MIF en-
hances the differentiation of endothelial cells to
blood vessels.
45,46 In human breast cancer cells,
MIF over-expression correlates with IL-8 and VEGF
expression associated with angiogenesis.
47
MIF, enzymatic activity and
tumour progression
A unique functional characteristic of MIF, which sets
it apart from other cytokines is its enzymatic activ-
ity.
58 The precise role of this novel tautomerase en-
zymatic activity has not been fully defined. In
relation to cancer pathogenesis, investigators have
sought to define this enzymatic activity by both uti-
lizing catalytically inactive recombinant proteins
in vitro and in animal models by using a transgenic
mouse expressing enzymatically inactive MIF.
59 The
P1G mouse expresses a mutated MIF where a ter-
minal proline has been replaced by a glycine result-
ing in specific loss of this enzymatic activity. While
binding of MIF to CD74 and JAB1 was not signifi-
cantly reduced, the mutation eliminated MIF en-
zymatic activity and intriguingly impaired specific
MIF biological activity. With regard to cancer
animal models, chemically induced skin tumours
are less effectively induced in P1G mutant mice.
This work suggests that apart from a potential
role for the enzymatic activity, the tautomerase site
is also required for important protein–protein
interactions.
Small molecular weight inhibitors of MIF tauto-
merase activity have also been used to dissect out
the importance of this unique activity in cancer
pathogenesis. ISO-1 is one such inhibitor designed
to fit into the catalytic site of MIF.
60 Using colorectal
cancer as a model where serum concentration of
MIF have been shown to correlate with increased
risk of metastasis to the liver, in vivo treatment of
colon carcinoma-bearing mice with ISO-1 results in
decreased tumour volume, reduced angiogenesis
and less liver metastasis.
61 ISO-1 has also been
shown to restore dexamethasone sensitivity in
glioma cells which inhibits MIF-induced promotion
of migration and invasion of the cells via MAP kin-
ases. Both enzyme kinetic studies and in vivo tox-
icity studies suggest a limited role for ISO-1 in
human studies. However, our expanding knowledge
of this novel enzymatic activity in human disease
provides the rationale for the further development
of more refined small molecular weight enzymatic
inhibitors targeting specifically this novel activity.
It is our conjecture that individuals who are
genetically predisposed to exhibit chronic injurious
inflammation are at enhanced risk of cancer pro-
gression. Our expanding knowledge of MIF biology
now includes a greater understanding of its ability to
both directly promote tumour growth and indirectly
create a nurturing local tumour microenvironment,
as well as insight into the genetic regulation of MIF
expression. Increasingly, this evidence highlights
MIF, as a prime therapeutic target in patients with
augmented inflammatory responses that predispose
to cancer development.
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